secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-05-13T20:05:18+00:00
Accession:  0001193125-26-221593
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured
--------------------------------------------------------------------------------

- Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.
- RAINIER trial on track for completion and Phase 2 dose selection by year-end 2026.
- Q1 2026 cash position $14.5M; raised $0.9M net under SEPAs; secured new $60M SEPA with Yorkville.
- Jeff Lamothe appointed CEO; Marvin White transitions to Executive Chair.
- Leadership believes the $60M facility extends capital access into 2029 through key catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526221593/0001193125-26-221593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526221593/apvo-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer